As per the terms of the agreement, ImmunGene is entitled to get undisclosed fees which include upfront payment from Cephalon Australia a four-year option to leverage ImmunGene’s novel drug development technology in preclinical research on up to six of Cephalon Australia’s drug candidates.
Under the pact, Cephalon Australia will do research, clinical development, manufacturing and commercialization of products that result from the ImmunGene collaboration.
Additionally, Cephalon Australia will also make considerable payments to ImmunGene for research, clinical and regulatory milestones for each drug candidate in the collaboration that is commercialized, in addition to royalties on worldwide net sales of any resulting products.
ImmunGene CEO Sanjay Khare this collaboration is a validation of ImmunGene’s novel antibody function enhancement technology that adds the power of cytokines to antibodies while reducing the systemic toxicity of the cytokines.